Currently Recruiting

Currently Recruiting

Currently Recruiting

The following studies are either currently enrolling new patients or are pending approval by the Institutional Review Board and should be enrolling shortly:

Retinal Diseases

  • A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Comparethe Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (DERBY)
    Contact: Rishi Singh, MD (216.445.9497) or Angela Meador (216.445.7176)
  • A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration (PANDA)
    Contact: Katherine Talcott, MD (440.988.4040) or Tyler Mullen (216.445.3840)
  • A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KESTREL)
    Contact: Aleksandra Rachitskaya, MD (216.444.2030) or Tyler Mullen (216.445.3840)
  • A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study To Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema (RHINE)
    Contact: Sumit Sharma, MD (216.445.4904) or Angela Meador (216.445.7176)
  • A Randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of Orally administered BI 1467335 for 12 weeks with a 12 week follow up period in patients with Nonproliferative diabetic retinopathy without center-involved diabetic macular edema (ROBIN study)
    Contact: Justis Ehlers, MD (216.445.2226) or Laura Stiegel (216.636.0183)
  • A Randomized Trial of Intravitreous Aflibercept versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema
    Contact: Aleksandra Rachitskaya, MD (216.444.2030) or Angela Meador (216.445.7176)
  • AERIE AR-1105-CS201 A multi-center, open label, safety and proof-of-concept study to assess safety, tolerability and efficacy of AR-1105 in subjects with macular edema due to retinal vein occlusion (RVO)
    Contact: Rishi Singh, MD (216.445.9497) or Pam Donati (216.444.3735)

Uveitis

  • A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Noninfectious Uveitis
    Contact: Sumit Sharma, MD (216.445.4904) or Emily Fisher (216.445.1649
  • LUMINA: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 μg DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
    Contact: Sumit Sharma, MD (216.445.4904) or Kim Baynes (216.444.2566)

Pediatric

  • Study of Luminopia One Digital Therapeutic as Amblyopia Treatment
    Contact: Fatema Ghasia, MD (216.444.2020) or Pam Donati (216.444.3735)

Gene Therapy

  • A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients with Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
    Contact: Elias Traboulsi, MD (216.444.4363) or Tyler Mullen (216.445.3840)
  • A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)
    Contact: Elias Traboulsi, MD (216.444.4363) or Tyler Mullen (216.445.3840)

Cornea and Refractive Surgery

  • A Phase 2 Open Label Trial of ST266 Eye Drops In The Treatment of Persistent Corneal Epithelial Defects (Noveome)
    Contact: William J. Dupps, MD, PhD (216.444.8396) or Angela Meador (216.445.7176)

Other

  • A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single Or Multi-Dose Intravitreal Injection(s) To Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
    Contact: Gregory Kosmorsky, DO (216.444.2855) or Tyler Mullen (216.445.3840)
Past Studies

Past Studies

The studies below have completed patient enrollment in the last year at Cole Eye Institute and are in follow-up:

  • Pediatric Cataract Surgery Outcomes Registry (CO2) (Elias Traboulsi, MD)
  • Glasses versus Observation for Moderate Hypermetropia in Young Children (Elias Traboulsi, MD)
  • A Phase-3 Randomized Double-masked Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (anti-PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age Related Macular Degeneration (Rishi Singh, MD)
  • The Infant Aphakia Treatment Study (Elias Traboulsi, MD)
  • Intermittent Exotropia Study 1; A Randomized Trial of Bilateral Lateral Rectus Recession versus Unilateral Lateral Rectus Recession with Medial Rectus Resection for Intermittent Exotropia, Extension (Elias Traboulsi, MD)
  • Long Term Safety Follow-up for Subjects Previously Implanted with the AcrySof® CachetT Phakic Lens in Clinical Studies C-02-23, C-02-40, C-03-21 and C-05-57” (William J. Dupps, MD)